Retrospective cohort analysis highlights erythropoietin-stimulating agents impact on outcomes in myelodysplastic syndromes.
Key Points
Transfusion independence rates were higher in untreated patients compared to those receiving erythropoietin-stimulating agents, indicating better baseline health.
Among 561 patients, 25.5% had higher-risk myelodysplastic syndromes and transformation to acute myeloid leukemia reached 51.7%.
Retrospective cohort analysis from 2019-2024 provides comprehensive data on treatment patterns for myelodysplastic syndromes.
Overall survival in lower-risk myelodysplastic syndromes patients receiving treatments varied, showing the direct influence of specific therapies.